Avricore Health Reports Third-Quarter 2022 Results
29 nov. 2022 11h08 HE
|
Avricore Health Inc.
VANCOUVER, British Columbia, Nov. 29, 2022 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) today released its Q3 results which demonstrate significant revenue growth,...
Final Results from Phase 2 INSTANT Trial of InRhythm™ for the Treatment of Newly Diagnosed and Recurrent Paroxysmal Atrial Fibrillation Presented at 2022 American Heart Association Scientific Sessions
07 nov. 2022 07h00 HE
|
InCarda Therapeutics, Inc.
Data Demonstrate Orally Inhaled Flecainide May Provide a Safe, Effective, and Convenient First-Line Treatment Option for Cardioversion of Recent-Onset Newly Diagnosed and Paroxysmal Atrial...
BioSig Signs Master Research Agreement with Cleveland Clinic to Explore Expanded Applications for its Digital Signal Processing Technology
24 oct. 2022 11h03 HE
|
BioSig Technologies, Inc.
Westport, CT, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Medical Center of Excellence to leverage the Company’s PURE EP™ System to further its research and educational objectives as a leader in cardiac...
BioSig Invited to Attend and Sponsor Venice Arrhythmias 2022
12 oct. 2022 10h00 HE
|
BioSig Technologies, Inc.
Westport, CT, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented...
$4.5+ Billion Artificial Heart Market Size to Exhibit CAGR of 15+% by 2028, Deep Dive Analysis of Key Players and Growth Opportunities
12 oct. 2022 09h16 HE
|
The Insight Partners
New York, Oct. 12, 2022 (GLOBE NEWSWIRE) -- The Insight Partners recently published a report on "Artificial Heart Market Size, Share, Trends, Growth Strategy and Forecast to 2028 – COVID-19 Impact...
BioSig Executes Purchase Agreement with Methodist Hospital, San Antonio and Expands Customer Base
07 oct. 2022 09h35 HE
|
BioSig Technologies, Inc.
Westport, CT, Oct. 07, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented...
InCarda Therapeutics Announces Execution of Planned CEO Transition to Drive Next Phase of Corporate Growth
04 oct. 2022 07h00 HE
|
InCarda Therapeutics, Inc.
Robert Lisicki Appointed as New Chief Executive Officer and Board Member; Possesses Broad Commercial and Public Company Experience Grace E, Colón, Ph.D., Stepping Aside Following Nearly Ten Years as...
Heart Tumor Market Size Worth USD 1.36 Billion by 2030 at 8.5% CAGR - Report by Market Research Future (MRFR)
29 sept. 2022 02h30 HE
|
Market Research Future
New York, USA, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Heart Tumor Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), “Heart Tumor Market Information By...
BioSig Launches PURE EP™ Software Version 6 with ACCUVIZ™ Module
22 sept. 2022 09h00 HE
|
BioSig Technologies, Inc.
Westport, CT, Sept. 22, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering...
Introducing Fox & Muse: Integrating Dating, Security, and Luxury
08 sept. 2022 11h00 HE
|
Fox & Muse
AUSTIN, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- On the heels of Tinder Swindler, it's a commonly-known fact that the dating space is saturated with the likes of fakes, scammers, catfish, and...